










































Discovery of drug-like inhibitors of an essential RNA-editing
ligase in Trypanosoma brucei
Citation for published version:
Amaro, RE, Schnaufer, A, Interthal, H, Hol, W, Stuart, KD & McCammon, JA 2008, 'Discovery of drug-like
inhibitors of an essential RNA-editing ligase in Trypanosoma brucei' Proceedings of the National Academy
of Sciences, vol 105, no. 45, pp. 17278-17283. DOI: 10.1073/pnas.0805820105
Digital Object Identifier (DOI):
10.1073/pnas.0805820105
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Proceedings of the National Academy of Sciences
Publisher Rights Statement:
Freely available online through the PNAS open access option.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Discovery of drug-like inhibitors of an essential
RNA-editing ligase in Trypanosoma brucei
Rommie E. Amaroa,1,2, Achim Schnauferb,1,2, Heidrun Interthalc, Wim Hold,e,f, Kenneth D. Stuartb,g,
and J. Andrew McCammona,h,i
aDepartment of Chemistry and Biochemistry and Center for Theoretical Biological Physics, University of California at San Diego, La Jolla, CA 92093-0365;
bSeattle Biomedical Research Institute, Seattle, WA 98109; cDepartment of Microbiology, dDepartment of Biochemistry, eBiomolecular Structure Center,
fBiomolecular Structure and Design (BMSD) Graduate Program, and gDepartment of Pathobiology, University of Washington, Seattle, WA 98195;
hDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093-0365; and iHoward Hughes Medical Institute, University of
California at San Diego, La Jolla, CA 92093-0365
Edited by José N. Onuchic, University of California at San Diego, La Jolla, CA, and approved September 23, 2008 (received for review June 17, 2008)
Trypanosomatid RNA editing is a unique process and essential for
these organisms. It therefore represents a drug target for a group
of protozoa that includes the causative agents for African sleeping
sickness and other devastating tropical and subtropical diseases.
Here,we present drug-like inhibitors of a key enzyme in the editing
machinery, RNA-editing ligase 1 (REL1). These inhibitors were
identified through a strategy employing molecular dynamics to
account for protein flexibility. A virtual screen of the REL1 crystal
structure against the National Cancer Institute Diversity Set was
performed by using AutoDock4. The top 30 compounds, predicted
to interactwith REL1’s ATP-binding pocket, were further refined by
using the relaxed complex scheme (RCS), which redocks the com-
pounds to receptor structures extracted from an explicitly solvated
molecular dynamics trajectory. The resulting reordering of the
ligands and filtering based on drug-like properties resulted in an
initial recommended set of 8 ligands, 2 of which exhibited micro-
molar activity against REL1. A subsequent hierarchical similarity
search with the most active compound over the full National
Cancer Institute database and RCS rescoring resulted in an addi-
tional set of 6 ligands, 2 ofwhichwere confirmed as REL1 inhibitors
with IC50 values of 1 M. Tests of the 3 most promising com-
pounds against the most closely related bacteriophage T4 RNA
ligase 2, as well as against human DNA ligase III, indicated a
considerable degree of selectivity for RNA ligases. These com-
pounds are promising scaffolds for future drug design and discov-
ery efforts against these important pathogens.
molecular dynamics  relaxed complex scheme  RNA ligase 
African sleeping sickness  receptor flexibility
Many advances in our understanding of the fundamentalbiology of trypanosomatids (order Kinetoplastida) have
occurred over the past few decades, including the sequencing of
their genomes (1). Yet, the development of new and effective
drugs to treat the diseases caused by these protozoan parasites
has been relatively nonexistent. Each year, millions of people in
the poorest countries in the world suffer from the infectious
tropical diseases caused by these pathogens, including human
African trypanosomiasis (HAT), Chagas disease, and leishman-
iasis. These ‘‘orphan diseases’’ cause not only death, but also
contribute to a crippling cycle of poverty within the Americas,
Asia, and Africa, which collectively harbor a disproportionate
amount of the neglected disease burden (2). Existing drugs are
costly and difficult to deliver, induce debilitating or fatal side
effects, and are showing increased signs of resistance (3). As
telling as it is unfortunate, only 1 new drug against HAT has been
registered within the past 50 years (4).
A unique aspect of the biology of these protozoan parasites is
that most of their mitochondrial mRNAs undergo extensive
editing in the form of internal uridine insertion and removal,
catalyzed by large, multiprotein complexes known as editosomes
and directed by guide RNAs (gRNAs) (5). Although all of the
components of the editosome are not yet fully characterized,
decades of study have allowed many intriguing details to emerge,
in particular, with respect to the 20S editosomes (5). These
complexes exist in at least 3 different forms with respect to their
endonuclease component. Each of the 3 complexes comprises
14–15 proteins and appears to be highly dynamic (6).
The editing process is initiated by endonucleolytic cleavage at
a site of mismatch identified when a premRNA is bound by its
cognate gRNA, a 50- to 60-nt transcript complementary to a
so-called anchor region in the premRNA as well as to the edited
version of that RNA. The type of RNA mismatch determines
which 20S editosome catalyzes the cleavage reaction. As speci-
fied by the gRNA sequence, U’s are then either added, by the
terminal uridylyl transferase (TUTase) RET2, or deleted by a
U-specific 3-exoribonuclease (ExoUase). The processed RNA
fragments are then religated by 1 of 2 RNA ligases, RNA editing
ligase 1 (REL1) or 2 (REL2). REL1 has been shown to play a
key role in the viability of Trypanosoma brucei, as it is required
for survival of both the insect and bloodstream forms of the
pathogen (7, 8). In addition, it is a particularly attractive drug
target because there are no known close human homologs.
Virtual screening (VS) is a widely used computational method
to identify inhibitors out of a large database of compounds (9).
The treatment of receptor flexibility within the scope of VS is
still in its infancy and a very active area of research, because it
is widely accepted that receptor flexibility plays an important
role in molecular recognition (10). A promising approach is the
relaxed complex scheme (RCS), a hybrid computational method
that combines the advantages of docking algorithms with dy-
namic structural information provided by molecular dynamics
(MD) simulations (11, 12). The use of structural information
provided from all-atomMD simulations allows us to incorporate
ensemble-based information into the drug discovery and design
process, whereas conventional VS techniques typically consider
only 1 or a few static receptor structures. The incorporation of
dynamic receptor information, although computationally more
intensive, can discover and take advantage of new binding
pockets (13, 14) and improve the ranking of predicted com-
pounds. To our knowledge, the RCS is the only computational
technique that exploits full-receptor main-chain flexibility, al-
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though techniques allowing side-chain and limited receptor
backbone flexibility have been developed (15–17). An important
example of the success of the RCS was demonstrated with
raltegravir, the first FDA-approved drug-targeting HIV inte-
grase (18, 19).
In this work, we present 5 drug-like inhibitors of T. brucei
REL1, which we discovered through an improved RCS, inte-
grated within a VS approach. The high-resolution crystal struc-
ture of TbREL1 (20) provides an excellent platform for rational
drug design as well as for MD simulations. A 20-ns simulation
was used to investigate the dynamics of TbREL1 (21), and the
resulting structures were used in conjunction with the RCS to
predict the most promising compounds. Through the use of QR
factorization, we are able to distill the structural ensemble
generated through the MD simulations to a nonredundant set,
thus significantly reducing the computational expense. In vitro
inhibition assays of the first step in the ligation reaction and tests
for nonspecific inhibition through aggregation confirmed at least
3 inhibitory compounds with IC50 values in the low-micromolar
range. The top compounds were also tested against 2 related and
1 unrelated ATP-binding protein to investigate off-target activ-
ity. Ultimately, we show that the use of receptor flexibility in the
VS process provided an important enrichment of the recom-
mended set of compounds, resulting in the discovery of several
promising scaffolds that may aid in the development of new
drugs against several devastating tropical diseases.
Results and Discussion
Initial Set of Recommended Compounds. The initial VS of the
National Cancer Institute (NCI) Diversity Set used the static
TbREL1 crystal structure to dock and rank 1,800 compounds
according to their predicted binding affinity. Typical VSs use a
single crystal structure to predict the binding affinity of the
compounds in the screening set. To take receptor flexibility into
account and to validate and refine the top hits, the top 2% of the
screening hits (corresponding to the top 30 compounds), all of
which were predicted to interact with the ATP-binding pocket,
were redocked into the full holoMD ensemble (Fig. 1). This RCS
rescoring created a so-called binding spectrum for each com-
pound and the mean of this binding spectrum energy (i.e., RC
energy) was used to rank-order the compounds. The RC energy
ranking reordered the top compounds such that several com-
pounds that ranked poorly in the crystal structure screen were
subsequently ranked as the best compounds (Table 1). An
additional filtering of the compounds according to Lipinski’s
rules was performed, allowing us to focus our search on the most
promising drug-like candidate compounds.
To improve the efficiency of the RCS, we reduced the
structural ensemble used for redocking with the QR factoriza-
tion algorithm (22). This technique was originally developed to
remove inherent bias in structure databases and distill, from a
vast quantity of redundant information, a minimal basis set of
protein structures that accurately spans the evolutionary con-
formation space of a particular protein. Here, we incorporate the
QR factorization to generate a nonredundant and representative
set of structures spanning the configurational space sampled in
the MD simulations. This algorithm reduced the initial set of 400
structures to 33 (supporting information (SI) Fig. S1). Notably,
a comparison of the mean RC energy and the mean QR-RC
energy for the top 30 compounds was very close (R2  0.9932),
indicating that redocking into the QR-reduced set is a more
efficient way to capture the effects of receptor flexibility without
loss of binding spectrum information (Table 1). The integration
of QR to the RCS resulted in 90% decrease in computational
cost for the redocking calculations, providing an order of
magnitude speedup. The top 8 compounds were recommended
for experimental testing (Table 1 and Table S1).
Low-Micromolar Inhibitors Found in Round 1. The first step in the
reaction pathway of RNA and eukaryotic DNA ligases is the
reaction of a lysine residue with ATP to form a covalent
enzyme-AMP intermediate (adenylylation reaction). Measuring
formation of TbREL1-[32P]AMP by SDS/PAGE and autora-
Fig. 1. An overview of the relaxed complex scheme with virtual screening
procedure is shown. The first screen is performed with the crystal structure and
the NCI diversity set with AutoDock4 (AD4). MD simulations are performed
with the solvated crystal structure, generating the receptor ensemble. The
compounds can be docked into the full ensemble (400 structures) or a reduced
set, here determined with QR factorization (QR ensemble, 33 structures). The
reordered compounds are then selected for experimental testing.




structure BE RC-mean BE RC-QR-mean BE
Rank from crystal
structure screen
% Activity at 10 M,
with TX-100
V1 45208 9.92 12.13 12.06 16 43.1
V2 7223 10.97 11.98 11.89 8 N.I.*
V3 125908 10.76 11.73 11.74 15 87.2
V4 117079 11.59 11.39 11.25 2 68.5
V5 601364 11.07 11.01 10.97 7 N.I.
V6 45544 11.25 10.89 10.73 5 N.I.
V7 9600 12.61 10.33 10.48 1 N.I.
V8 117269 11.32 8.09 8.04 4 N.I.
The compound ID, NSC number, predicted binding energy (BE) based on the single static crystal structure (Crystal Structure BE), mean
binding energy based on the full receptor ensemble (RC-mean BE), reduced representative ensemble (RC-QR-mean BE), rank from the
crystal structure screen, and percent TbREL1 activity at 10 M concentration of inhibitor and 0.1% Triton X-100 (TX-100) (% Activity at
10 M; N.I. denotes not inhibiting; *, denotes compound is an aggregator in our assays).














diography, we tested the initial recommended set for their ability
to inhibit the adenylylation reaction (Fig. S2A). The assay was
carried out at 10 M compound concentration in the presence
of 0.1% Triton X-100 as a first measure to select against any
promiscuous, aggregate-based inhibitors (23). Two compounds,
V1 [4,5-dihydroxy-3-(1-naphthyldiazenyl)-2,7-naphthalenedisul-
fonic acid] and V4 [1-amino-4-(3-(aminosulfonyl)anilino)-9,10-
dioxo-9,10-dihydro-2-anthracenesulfonic acid] (Fig. 2) inhibited
TbREL1 adenylylation by57% and31%, respectively (Table
1 and Fig. S2A). Another compound, V2 [3-hydroxy-4-((1-
hydroxy-2-naphthyl)diazenyl)-7-(hydroxy(oxido)amino)-1-
naphthalenesulfonic acid], showed complete inhibition at 10 M
in the absence of detergent (data not shown). Addition of 0.1%
Triton X-100 to the assay completely restored activity and,
therefore, that inhibitor was categorized as aggregate-based and
not analyzed further. Interestingly, some of the compounds
appear to up-regulate adenylylation activity (Fig. S2A), possibly
because of small amounts of denaturing agent facilitating struc-
tural transitions (24). Subsequent studies focused on the best hit,
compound V1.
Inhibition by V1 was not significantly influenced by the
presence of 0.1 mg/mL BSA (Fig. S3A), again ruling out non-
specific, aggregate-based inhibition (25). We determined an IC50
for V1 of 1.95  0.33 M (Fig. 3). Comparison with bacterio-
phage T4 RNA ligase 2 (T4Rnl2; refs. 26 and 27) and human
DNA ligase III (HsLigIII; ref. 28) indicated considerable
selectivity for RNA vs. DNA ligases: V1 inhibited adenylylation
of T4Rnl2 and HsLigIII with IC50s of 3.53  1.17 M and
27.49  6.40 M, respectively. Luciferase, an unrelated but also
ATP-dependent enzyme, was not affected up to 3 mM, the
highest concentration tested (data not shown).
Hierarchical Search over the Full NCI Database.Hierarchical screen-
ing is an efficient strategy that allows an initial broad search over
a chemically and pharmacologically diverse set of compounds,
followed by a focused search over a much larger database to find
molecules related to potential lead compounds (29). A similarity
search over the full NCI database with V1 resulted in 117
compounds, which we docked to the TbREL1 crystal structure
and ranked according to predicted binding energy. The top
compounds based on a binding energy cutoff of 12 kcal/mol
(corresponding to the top 10% of the similarity set) were then
redocked into the QR ensemble. The resulting QR binding
spectrum energy was used for the final ranking and the top 6
compounds with the highest affinity for TbREL1 were selected
for experimental testing (Table 2).
Related Compound S5 Showed Increased Inhibition. The 6 best
compounds identified in the similarity screen were tested at 10
M concentration in the adenylylation assay, as above, carried
out in the presence of 0.1% Triton X-100 (Fig. S2B and Table
S2). Two compounds, S5 [3-((4-(ethylamino)phenyl)diazenyl)-
4,5-dihydroxy-2,7-naphthalenedisulfonic acid] and S1 [3-((5-
chloro-2-hydroxyphenyl)diazenyl)-4,5-dihydroxy-2,7-naphtha-
lenedisulfonic acid] (Fig. 2, Fig. S2, and Table 2) strongly
inhibited TbREL1 activity.
Addition of 0.1 mg/mL BSA had no significant effect on
inhibition for either of these 2 compounds, confirming that they
do not act through aggregation (Fig. S3B and data not shown).
Fig. 2. Structures of the 5 inhibitors discovered. The chemical structures of
the 5 drug-like, low-micromolar inhibiting compounds presented in this work.
Fig. 3. First round of inhibitor testing. Dose–response curve for V1 vs.TbREL1
(solid line, circles), T4Rnl2 (dashed line, squares), and HsLigIII (dotted line,
triangles). Corresponding IC50 and R2 values are listed beneath.
Table 2. Second set of compounds based on similarity to V1
Compound ID NSC No. Crystal structure BE RC-QR-mean BE % Activity at 10 M, with TX-100
S1 100234 14.05 11.85 8.6
S2 45207 12.99 11.47 N.I.
S3 7829 12.88 10.95 N.I.
S4 86033 12.55 10.02 N.I.
S5 16209 12.73 9.95 4.1
S6 45201 12.79 9.84 98.6
The compound ID, NSC number, predicted binding energy (BE) based on the single static crystal structure (Crystal Structure BE), mean
binding energy based on the full receptor ensemble (RC-mean BE), reduced representative ensemble (RC-QR-mean BE), rank from the
crystal structure screen, and percent TbREL1 activity at 10 M concentration of inhibitor and 0.1% Triton X-100 (TX-100) (% Activity at
10 M; N.I. denotes not inhibiting).
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Dose–response curves established IC50 values of 1.01 0.16 M
and 1.95  0.61 M for S5 and S1, respectively (Fig. 4). For S5,
this reflects an approximately 2-fold decrease compared with V1.
Interestingly, IC50 values for T4Rnl2 and HsLigIII decreased
3.5- and 4.2-fold, respectively. For S1, IC50 values for all 3
ligases were not significantly different from V1. The control
enzyme luciferase was not affected up to 1 mM, the highest
concentration tested for both S5 and S1 (data not shown).
Predicted Modes of Binding for the Top 3 Compounds. The 3 micro-
molar drug-like inhibitors of TbREL1 that we have identified,
V1, S5, and S1, all share a core 4,5-dihydroxy-2,7-naphtha-
lenedisulfonic acid scaffold, which is predicted to bind in the
deep ATP-binding cleft (Fig. 5). Based on our RCS calculations,
we expect S3 and S6, which share the core scaffold, to also inhibit
TbREL1, albeit at higher concentrations than tested here.
Comparison of V1 with S2 suggests that maintaining both
hydroxyl groups may be an important feature, because the
compounds are identical with the exception of the hydroxyl
group on position 5 (Tables S1 and S2). The core scaffold,
including several hydrogen-bonding interactions with the back-
bone groups of V88, E86, and the side chain of R111, conserves
many protein–ligand interactions previously occupied by ATP
(Fig. 5). The naphthalene group conserves aromatic pi-stacking
interactions between the adenosine ring and F209. On the
opposite side of the ring, hydrophobic interactions are main-
tained with the side chain of V286. Interestingly, the C7 sulfonic
acid group in all 3 compounds is predicted to replace a critical
water molecule bridging a hydrogen bond network between
R288, D210, the backbone carbonyl of F209, Y58, and the N1
atom of the adenosine ring (Fig. S4). Toward the periphery of the
binding site, the aromatic rings in all of the compounds are in
position to form cation–pi interactions with R309 or R111.
Because of their varying chemical structure, compounds V1,
S1, and S5 are predicted to differ in their receptor interactions
near the periphery of the binding site. The top compound, S5,
may benefit from an additional hydrogen bond formed between
the amino group in its ethylamino-phenyl group and the back-
bone carbonyl of G90, as well as hydrophobic interactions
between T91 and the ethyl group. Compared with S6, the
differences on the para-substituent account for a large difference
in activity (Table S2 and Fig. S2B). In the lowest-energy and
most populated predicted binding modes the para-substituent is
placed on the periphery of the binding site, and we speculate that
the dynamics of residues G90, T91, and N193 may account for
these differences (Fig. S1). Further optimizations of the core
scaffold may increase the affinity of binding, such as extensions
of hydrogen-bonding groups on the C8 atom of the naphthalene
moiety or a small hydrophobic group on the C1 atom.
Receptor Flexibility in Computer-Aided Drug Design. The develop-
ment of methodologies for computer-aided drug design depends
on the critical compromise between accuracy and computational
costs. Ideally, the most reliable prediction of molecular affinity
can be obtained through rigorous free-energy calculations of the
ligand-binding process (ref. 30 and references within); however,
these techniques are prohibitively expensive for use in VS
experiments. In this work, we combined VS with all-atom MD
simulations in an approach we call the relaxed complex scheme
(Fig. 1). The use of QR factorization to reduce structural
redundancy in our MD-generated receptor ensemble enabled us
to accommodate full receptor flexibility in a computationally
feasible approach.
Two of the best inhibiting compounds from the first round, V1
and V3, were initially ranked 16th and 15th in the crystal
structure screen and therefore would not have been selected for
testing based on the crystal structure screen alone. Remarkably,
V1 was correctly predicted to be the best inhibitor, and the other
inhibiting compounds identified in the first round of testing were
reordered to the top of the list based on their predicted rankings
by the RC-QR mean binding energy (Table 1). We note,
however, that they are not rank-ordered correctly. Still, the
success of these predictions underscores the importance of
incorporating receptor flexibility in docking and scoring meth-
ods. Further refinement of the predicted compounds based on
the RCS reranking provided an important enrichment of the
final ranked set, resulting in a hit rate (at 10 M concentration)
Fig. 4. Second round of inhibitor testing. (A) Dose–response curve for S5 vs.
TbREL1 (solid line, circles), T4Rnl2 (dashed line, squares), andHsLigIII (dotted
line, triangles). Corresponding IC50 and R2 values are listed beneath. (B) Same
for S1.
Fig. 5. Predicted binding mode ofS5. The most populated and lowest energy
pose is shown for S5 docked into the TbREL1 crystal structure. S5 is shown in
ball and stick, with carbons in green, nitrogens in blue, sulfur in yellow, oxygen
in red, and hydrogens in white. Hydrogen bonds and salt-bridge interactions
are shown with black lines. The protein residues are shown in licorice, with the
same coloring except for carbons, which are cyan.














of 38%. The secondary hierarchical screening, the result of a
similarity search for compound V1, resulted in a hit rate of 33%.
Potential Off-Target Activity. As an example for a related host
protein, we experimentally tested the identified inhibitors
against the human DNA ligase III (to date, no human RNA
ligases have been identified) and showed that these compounds
have 6- to 36-fold selectivity for the trypanosomal target (Figs.
3 and 4). Docking of all 3 compounds to human DNA ligase I
(1X9N; ref. 31) indicates that this may be due, in part, to
differences in the depth of the ATP-binding pocket between the
human and trypanosomal ligase and in residues on the periphery
of the active site (data not shown). Efforts to reduce off-target
activity can be pursued by strategically modifying these com-
pounds in ways that exploit structural differences between the
ATP-binding sites of DNA and RNA ligases, in particular,
REL1, that have been identified through a structural phyloge-
netic analysis of the superfamily (21). Although 8 residues are
strictly conserved within the 5 core motifs, residues flanking the
core motifs vary among the superfamily members. For example,
several key ATP-binding residues flanking motifs I, IV, and V,
namely C85, N92, R288, and I305 (TbREL1 numbering), create
a binding site topology in TbREL1 distinct from the human
DNA ligases. Modifications to the core scaffolds that take
advantage of these differences may provide additional selectivity
for TbREL1 over the human enzymes.
Dye-Like Compounds as Antitrypanosomal Therapeutics. The use of
dyes as therapeutics has a rich history, beginning in 1891 with the
reporting of methylene blue as a potent antimalarial by Guttman
and Ehrlich (32). Ehrlich also had interest in developing com-
pounds against HAT and discovered antitrypanosomal activity
in mice with the dyes Trypan Red and Trypan Blue. Although
these compounds were not active in humans, chemical modifi-
cations of the azo linkage to reduce the compounds’ tissue-
staining capacity led to the discovery of suramin, which is still
used today (33).
The 3 best inhibitors we have identified are all azo dyes and
similar to suramin in that they are polysulfonated naphthyl
compounds. Although suramin’s mode of trypanocidal action is
still a matter of debate, it is known to be quite promiscuous in
terms of inhibitory activity. TbREL1 does not appear to be a
target of this drug, however, because dyskinetoplastic trypano-
somes, which do not rely on RNA editing (34), are usually
susceptible to treatment with suramin (35). Suramin binds to
plasma proteins through its charged sulfonate groups (36).
Although such groups are shared between suramin and our top
compounds, the lack of an effect of BSA on their activity suggests
that they do not have high affinity for this plasma protein (Fig.
S3). This may indicate a generally lower promiscuity relative to
suramin, although more extensive biochemical assays with gly-
colytic enzymes, dehydrogenases, and kinases are warranted.
The latter 2 groups of enzymes are known to bind sulfonated
aromatic groups (37), albeit with different chemical structures
than the compounds presented here.
The discovery of these smaller, soluble compounds as new
antitrypanosomal drug leads has important pharmacological
implications. The potential to develop orally available drugs and
therapeutics that do not rely on membrane transporter proteins
is a key challenge facing HAT therapeutics, because reduced
drug uptake has been shown to be a mechanism of drug
resistance in African trypanosomes (38). These smaller and
significantly less charged (compared with suramin) drug-like
compounds, which were strictly chosen to obey all of the Lipinski
rules, may be able to passively diffuse through membranes or use
other transport mechanisms.
Conclusions
Despite many great advances in the understanding of trypano-
somal biology over the past few decades—including the sequenc-
ing of the genomes of representatives for the 3 major trypano-
somid pathogen groups—little of this knowledge has so far been
exploited to developmore effective drugs against these parasites.
To address this pharmaceutical need, a cooperative effort be-
tween academia and the pharmaceutical industry is urgently
needed. In this work, we present 5 compounds that are active
against an editosome enzyme required for the viability of T.
brucei, which we hope will provide promising scaffolds for future
drug discovery and design efforts against these parasites. The
fact that 3 of the compounds are dye derivatives may bode well
for future development, both in terms of the cost of manufac-
turing and bioavailability. Importantly, these compounds were
discovered through a computational scheme that combines VS
experiments with all-atomMD simulations in an ensemble-based
approach to drug discovery. The method we present here, which
takes advantage of advances in computer hardware and software
algorithms, provides a flexible receptor drug discovery scheme
that is significantly reduced in computational expense. This
approach is widely applicable to nearly any biological target and
provides encouraging evidence for the advantages of moving to
ensemble-based approaches in scientific discovery.
Materials and Methods
Target and Compound Preparation and Screening Protocol. A VS of the NCI
Diversity Set (NCIDS) database was performed with the original crystal struc-
ture by using AutoDock4 (AD4) (39, 40). The 1.2-Å resolution 1XDN crystal
structure ofTbREL1 was used to optimize the AD4 parameters as a control case
(20). In this benchmark, ATP and its coordinated magnesium ion were re-
docked into the crystal structure. For the receptor, protonation states of all
residues were assigned according to a pH of 7.0 by using the PDB2PQR web site
(41). The resulting PDB was processed with the AD4 receptor preparation
script. The C4 atom in the bound ATP was chosen as the grid center and the
grid contained 60  60  60 grid points with 0.375-Å spacing. See SI Text for
a detailed description of the AD4 parameter optimization.
The optimized AD4 parameters were used to screen the NCIDS (42, 43);
1,823 compounds were screened. The ligand files were processed with
AutoDockTools v1.4.5. All torsions were allowed to rotate through the Auto-
Tors program. The initial position and conformation were randomly assigned
and 100 dockings were performed. Top hits were filtered for drug-likeness by
their adherence to Lipinski’s ‘‘rule of fives’’ (44), because it has been recom-
mended that compounds conform to 2 or more of these rules (45). We applied
a more strict criterion, selecting compounds that conformed to all 4 rules.
Hierarchical Similarity Search. The top compound identified from the experi-
mental assays,V1, was used in a similarity search (i.e., hierarchical search) over
the full NCI database. A Tanimoto similarity index of 80% was used to identify
compounds with 80% or greater chemical similarity (46). These compounds
were then docked into the static receptor by using a similar procedure as
described above and used in the RCS as described below.
The Relaxed Complex Scheme. The top 30 compounds (corresponding to an
energy cutoff of 10.0 kcal/mol) were redocked to 400 snapshots extracted
from the ATP bound MD simulations at 50-ps intervals. The MD preparation,
details, and results are described elsewhere (21). New receptor grid files were
generated for each of the receptor structures. The ligand-docking parameters
were identical to those used for the VS, except that 20 docking runs were
performed for each ligand. The lowest docked energy poses were extracted
for each frame and the mean of the docking energies is reported for each as
RC-mean binding energy (BE).
Generating a Representative Ensemble from MD. To reduce the redundancy of
the MD-generated structures, a QR factorization method was used as imple-
mented in VMD 1.8.6 (47). The integration of this technique into the RCS has
been fully described in ref. 12. Use of a QH threshold of 0.86 to the REL1 MD
structures reduced the initial set of 400 structures to 33 (reducing the number
of dockings from 11,200 to 924), with essentially no loss of binding spectrum
information (Table 1).
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Compounds and Reagents. Compounds for biochemical screens were obtained
from the Developmental Therapeutics Program at the NCI, National Institutes
of Health, and dissolved in DMSO. Other reagents were from Sigma, unless
noted otherwise.
Recombinant TbREL1 Expression and Purification. See SI Text for a detailed
description. In brief, full-length TbREL1 was expressed in insect cells by using
the baculovirus system and purified via a C-terminal tandem affinity purifi-
cation (TAP) tag (48).
Enzymatic Assays and Curve Fitting. See SI Text for a detailed description
including buffer conditions. Adenylylation reactions with TbREL1 were per-
formed, essentially as described in ref. 20, in a volume of 20 L with 0.1 pmol
of protein and 1.8 Ci (30 nM) [-32P]ATP. Triton X-100 (0.1% wt/vol) or BSA
(0.1 mg/mL) were included as indicated. Adenylylation reactions with T4
phage RNA ligase 2 (T4Rnl2, New England Biolabs) and with human DNA
ligase III were performed with 1.8 Ci (30 nM) [-32P]ATP in 20-L reactions
containing 0.1 pmol and 1.2 pmol of protein, respectively.
Formation of enzyme–[32P]AMP complexes was analyzed by SDS/PAGE and
phosphorimaging (Storm, Molecular Dynamics). Inhibitor candidates, dis-
solved in DMSO, were included at the concentrations indicated and parallel
reactions with DMSO alone served as controls. All reactions were done in at
least triplicate. IC50 values were determined through nonlinear regression
analysis with the GraphPad Prism 5 software.
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